HRP20170027T1 - Postupci liječenja downovog sindroma, sindroma lomljivog kromosoma x i autizma - Google Patents
Postupci liječenja downovog sindroma, sindroma lomljivog kromosoma x i autizma Download PDFInfo
- Publication number
- HRP20170027T1 HRP20170027T1 HRP20170027TT HRP20170027T HRP20170027T1 HR P20170027 T1 HRP20170027 T1 HR P20170027T1 HR P20170027T T HRP20170027T T HR P20170027TT HR P20170027 T HRP20170027 T HR P20170027T HR P20170027 T1 HRP20170027 T1 HR P20170027T1
- Authority
- HR
- Croatia
- Prior art keywords
- baclofen
- preparation
- person
- accordance
- agonist
- Prior art date
Links
- 206010003805 Autism Diseases 0.000 title claims 4
- 208000020706 Autistic disease Diseases 0.000 title claims 4
- 208000001914 Fragile X syndrome Diseases 0.000 title claims 4
- 201000010374 Down Syndrome Diseases 0.000 title claims 2
- 206010044688 Trisomy 21 Diseases 0.000 title claims 2
- KPYSYYIEGFHWSV-QMMMGPOBSA-N Arbaclofen Chemical compound OC(=O)C[C@@H](CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-QMMMGPOBSA-N 0.000 claims 14
- 239000003477 4 aminobutyric acid receptor stimulating agent Substances 0.000 claims 10
- 229960000794 baclofen Drugs 0.000 claims 9
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims 6
- KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 claims 5
- 239000000556 agonist Substances 0.000 claims 5
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims 5
- 206010022998 Irritability Diseases 0.000 claims 4
- 230000003920 cognitive function Effects 0.000 claims 3
- 210000001766 X chromosome Anatomy 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 230000001773 anti-convulsant effect Effects 0.000 claims 2
- 239000001961 anticonvulsive agent Substances 0.000 claims 2
- 229960003965 antiepileptics Drugs 0.000 claims 2
- 229940124807 mGLUR antagonist Drugs 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims 1
- MGRVRXRGTBOSHW-UHFFFAOYSA-N (aminomethyl)phosphonic acid Chemical compound NCP(O)(O)=O MGRVRXRGTBOSHW-UHFFFAOYSA-N 0.000 claims 1
- 206010001488 Aggression Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 206010019191 Head banging Diseases 0.000 claims 1
- 108010065028 Metabotropic Glutamate 5 Receptor Proteins 0.000 claims 1
- 102100036834 Metabotropic glutamate receptor 1 Human genes 0.000 claims 1
- 102100038357 Metabotropic glutamate receptor 5 Human genes 0.000 claims 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 claims 1
- 150000001200 N-acyl ethanolamides Chemical class 0.000 claims 1
- 229940123925 Nicotinic receptor agonist Drugs 0.000 claims 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 1
- 206010044565 Tremor Diseases 0.000 claims 1
- 239000000384 adrenergic alpha-2 receptor agonist Substances 0.000 claims 1
- 230000001430 anti-depressive effect Effects 0.000 claims 1
- 230000000561 anti-psychotic effect Effects 0.000 claims 1
- 239000000935 antidepressant agent Substances 0.000 claims 1
- 229940005513 antidepressants Drugs 0.000 claims 1
- 230000009118 appropriate response Effects 0.000 claims 1
- 208000029560 autism spectrum disease Diseases 0.000 claims 1
- 230000006399 behavior Effects 0.000 claims 1
- 230000001149 cognitive effect Effects 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000002621 endocannabinoid Substances 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 230000006870 function Effects 0.000 claims 1
- 230000010365 information processing Effects 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 108010014719 metabotropic glutamate receptor type 1 Proteins 0.000 claims 1
- 230000036651 mood Effects 0.000 claims 1
- 230000008450 motivation Effects 0.000 claims 1
- 239000003149 muscarinic antagonist Substances 0.000 claims 1
- 239000000181 nicotinic agonist Substances 0.000 claims 1
- 229940044601 receptor agonist Drugs 0.000 claims 1
- 239000000018 receptor agonist Substances 0.000 claims 1
- 230000003252 repetitive effect Effects 0.000 claims 1
- 230000001953 sensory effect Effects 0.000 claims 1
- 230000002269 spontaneous effect Effects 0.000 claims 1
- 208000013623 stereotypic movement disease Diseases 0.000 claims 1
- 230000000007 visual effect Effects 0.000 claims 1
- 230000001755 vocal effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Claims (30)
1. Pripravak namijenjen upotrebi u poboljšavanju najmanje jednog člana kojeg se bira iz skupine koju čine socijalne vještine i komunikacijske vještine kod osobe s autizmom, naznačen time što pripravak sadrži terapijski djelotvornu količinu najmanje jednog agonista γ-aminomaslačne kiseline.
2. Pripravak namijenjen upotrebi u poboljšavanju najmanje jednog člana kojeg se bira iz skupine koju čine socijalne vještine i komunikacijske vještine kod osobe s poremećajem iz autističnog spektra, naznačen time što pripravak sadrži terapijski djelotvornu količinu najmanje jednog agonista γ-aminomaslačne kiseline.
3. Pripravak namijenjen upotrebi u liječenju osobe sa sindromom lomljivog kromosoma X, naznačen time što pripravak sadrži terapijski djelotvornu količinu najmanje jednog agonista γ-aminomaslačne kiseline.
4. Pripravak namijenjen upotrebi u liječenju osobe s Downovim sindromom, naznačen time što pripravak sadrži terapijski djelotvornu količinu najmanje jednog agonista γ-aminomaslačne kiseline.
5. Pripravak namijenjen upotrebi u poboljšavanju socijalnih vještina kod osobe s autizmom, naznačen time što pripravak sadrži terapijski djelotvornu količinu najmanje jednog agonista γ-aminomaslačne kiseline.
6. Pripravak namijenjen upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što agonist γ-aminomaslačne kiseline (GABA) uključuje agonist GABA(B).
7. Pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 3 ili patentnim zahtjevom 6, naznačen time što agonist GABA(B) uključuje baklofen, po mogućnosti R-baklofen.
8. Pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 7, naznačen time što je baklofen u najmanju ruku otprilike 80 molarnih postotaka R-baklofena, u najmanju ruku otprilike 85 molarnih postotaka R-baklofena, u najmanju ruku otprilike 90 molarnih postotaka R-baklofena, u najmanju ruku otprilike 95 molarnih postotaka R-baklofena ili u najmanju ruku otprilike 99 molarnih postotaka R-baklofena.
9. Pripravak namijenjen upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što dodatno uključuje primjenu na osobi najmanje jednog člana kojeg se bira iz skupine koju čine antidepresiv, α2-adrenergički agonist, antikonvulziv, agonist nikotinskog receptora, agonist endokanabinoidnog receptora, antikonvulziv, antipsihotik, agonist AMPA i antagonist muskarinskog receptora M1.
10. Pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 2 ili patentnim zahtjevom 5, naznačen time što osoba dodatno ima sindrom lomljivog kromosoma X.
11. Pripravak namijenjen upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što dodatno uključuje primjenu najmanje jednog antagonista mGluR iz Skupine I na osobi.
12. Pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 11, naznačen time što je antagonist mGluR iz Skupine I bilo antagonist mGluR5 ili antagonist mGluR1.
13. Pripravak namijenjen upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što dodatno uključuje poboljšavanje kognitivnih funkcija kod osobe.
14. Pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 13, naznačen time što je poboljšavanje kognitivnih funkcija poboljšavanje najmanje jednog člana kojeg se bira iz skupine koju čine pamćenje, učenje, pažnja, izvršne funkcije, obrada informacija, konceptualiziranje, pozornost i rješavanje problema.
15. Pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 2, naznačen time što pripravak sadrži terapijski djelotvornu količinu u najmanju ruku otprilike 90 molarnih postotaka R-baklofena u odnosu na ukupni R-baklofen i S-baklofen u pripravku.
16. Pripravak namijenjen upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što poboljšavanje socijalnih vještina kod osobe dodatno uključuje ublažavanje najmanje jednog člana kojeg se bira iz skupine koju čine opsesivno-kompulzivni poremećaj, poremećaj osjetilne prenadraženosti, anksiozni poremećaj, napadajni poremećaj, razdražljivost, agresivnost, tremor kod prepasti, repetitivno/autostimulacijsko ponašanje, gledanje u stranu, grizenje ruke, udaranje glave i udaranje drugih.
17. Pripravak namijenjen upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što poboljšavanje socijalnih vještina kod osobe uključuje poboljšavanje najmanje jednog člana kojeg se bira iz skupine koju čine socijaliziranje, prikladan odgovor na izgovoreni jezik, spontani pokušaji međudjelovanja, vizualni kontakt, raspoloženje, motiviranost i spokojnost.
18. Pripravak namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1, 2 ili 5, ili patentnih zahtjeva koji o njima ovise, naznačen time što dodatno uključuje poboljšavanje komunikacijskih vještina kod osobe.
19. Pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 18, naznačen time što poboljšavanje komunikacijskih vještina uključuje poboljšavanje verbalnog jezika.
20. Pripravak namijenjen upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što je pripravak namijenjen ublažavanje najmanje jednog člana kojeg se bira iz skupine koju čine razdražljivost i agresivnost kod osobe s autizmom.
21. Pripravak namijenjen upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se agonist γ-aminomaslačne kiseline, agonist GABA(B), baklofen ili R-baklofen primijenjuje oralno na osobi.
22. Pripravak namijenjen upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se agonist γ-aminomaslačne kiseline, baklofen ili R-baklofen primijenjuje na osobi u dozi od otprilike 2,5 mg, otprilike 5 mg, otprilike 10 mg, otprilike 15 mg, otprilike 20 mg, otprilike 25 mg, otprilike 30 mg, otprilike 40 mg, otprilike 45 mg, otprilike 50 mg ili otprilike 100 mg.
23. Pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 22, naznačen time što se agonist γ-aminomaslačne kiseline, baklofen ili R-baklofen primijenjuje u jednoj dozi dnevno, ili u dvije doze dnevno, ili tri doze dnevno, ili četiri doze dnevno, ili pet doze dnevno, ili u više doza dnevno.
24. Pripravak namijenjen upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što dolazi do poboljšanja najmanje jednog od socijalnih vještina, komunikacijskih vještina i kognitivnih vještina kod osobe nakon liječenja agonistom γ-aminomaslačne kiseline.
25. Pripravak namijenjen upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što dolazi do poboljšanja socijalnih vještina kod osobe.
26. Pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 24, naznačen time što dolazi do poboljšanja komunikacijskih vještina kod osobe.
27. Pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 24, naznačen time što dolazi do poboljšanja kognitivnih funkcija kod osobe.
28. Pripravak namijenjen upotrebi u ublažavanju najmanje jednog člana kojeg se bira iz skupine koju čine razdražljivost i agresivnost kod osobe sa sindromom lomljivog kromosoma X, naznačen time što pripravak sadrži terapijski djelotvornu količinu najmanje jednog agonista γ-aminomaslačne kiseline.
29. Pripravak namijenjen upotrebi u poboljšavanju najmanje jednog člana kojeg se bira iz skupine koju čine socijalne vještine i komunikacijske vještine kod osobe sa sindromom lomljivog kromosoma X, naznačen time što je pripravak oralni pripravak koji sadrži terapijski djelotvornu količinu u najmanju ruku otprilike 99 molarnih postotaka R-baklofena u odnosu na ukupni R-baklofen i S-baklofen.
30. Pripravak namijenjen upotrebi u ublažavanju najmanje jednog člana kojeg se bira iz skupine koju čine razdražljivost i agresivnost kod osobe sa sindromom lomljivog kromosoma X, naznačen time što je pripravak oralni pripravak koji sadrži terapijski djelotvornu količinu u najmanju ruku otprilike 99 molarnih postotaka R-baklofena u odnosu na ukupni R-baklofen i S-baklofen.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86073306P | 2006-11-22 | 2006-11-22 | |
| US156707P | 2007-11-02 | 2007-11-02 | |
| EP07862184.4A EP2083811B1 (en) | 2006-11-22 | 2007-11-21 | Methods of treating down's syndrome, fragile x syndrome and autism |
| PCT/US2007/024311 WO2008066750A1 (en) | 2006-11-22 | 2007-11-21 | Methods of treating mental retardation, down's syndrome, fragile x syndrome and autism |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20170027T1 true HRP20170027T1 (hr) | 2017-03-10 |
Family
ID=39272866
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20170027TT HRP20170027T1 (hr) | 2006-11-22 | 2017-01-10 | Postupci liječenja downovog sindroma, sindroma lomljivog kromosoma x i autizma |
Country Status (16)
| Country | Link |
|---|---|
| US (6) | US8143311B2 (hr) |
| EP (3) | EP2578216A1 (hr) |
| JP (1) | JP2010510314A (hr) |
| AU (1) | AU2007325836B2 (hr) |
| CA (1) | CA2670116C (hr) |
| CY (1) | CY1118406T1 (hr) |
| DK (1) | DK2083811T3 (hr) |
| ES (1) | ES2610508T3 (hr) |
| HR (1) | HRP20170027T1 (hr) |
| HU (1) | HUE032743T2 (hr) |
| LT (1) | LT2083811T (hr) |
| PL (1) | PL2083811T3 (hr) |
| PT (1) | PT2083811T (hr) |
| RS (1) | RS55585B1 (hr) |
| SI (1) | SI2083811T1 (hr) |
| WO (1) | WO2008066750A1 (hr) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2201950T (pt) * | 2008-12-08 | 2017-01-31 | Biocodex | Compostos e métodos para tratar doenças do espetro do autismo |
| ES2530047T3 (es) | 2009-02-12 | 2015-02-26 | Indiana University Research And Technology Corporation | Material y métodos para el tratamiento de trastornos del desarrollo que incluyen autismo idiopático y comórbido |
| US8334287B2 (en) | 2009-07-17 | 2012-12-18 | Hoffmann-La Roche Inc. | Imidazoles |
| WO2011053636A1 (en) * | 2009-10-27 | 2011-05-05 | Mount Sinai School Of Medicine | Methods of treating psychiatric or neurological disorders with mglur antagonists |
| EP2544688B1 (en) * | 2010-03-02 | 2016-09-07 | President and Fellows of Harvard College | Methods and compositions for treatment of angelman syndrome |
| WO2012009646A1 (en) * | 2010-07-15 | 2012-01-19 | Xenoport, Inc. | Methods of treating fragile x syndrome, down's syndrome, autism and related disorders |
| US8946206B2 (en) | 2010-12-17 | 2015-02-03 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for improving cognitive function |
| US9622997B2 (en) | 2012-06-01 | 2017-04-18 | Lynn Health Science Institute, Inc. | Methods for treating insomnia |
| JP2016506380A (ja) * | 2012-11-28 | 2016-03-03 | ニューレン ファーマシューティカルズ リミテッド | グリシル−ｌ−２−メチルプロリル−ｌ−グルタミン酸を使用する自閉症スペクトラム障害の処置 |
| US9265458B2 (en) | 2012-12-04 | 2016-02-23 | Sync-Think, Inc. | Application of smooth pursuit cognitive testing paradigms to clinical drug development |
| JPWO2014128882A1 (ja) * | 2013-02-21 | 2017-02-02 | 医療法人 和楽会 | 不安うつ病の治療薬 |
| US9380976B2 (en) | 2013-03-11 | 2016-07-05 | Sync-Think, Inc. | Optical neuroinformatics |
| HUE056551T2 (hu) * | 2013-10-14 | 2022-02-28 | Univ Indiana Res & Tech Corp | Az akamprozát alkalmazása az ERK 1-2 aktiváció modulálására az FXS és az ASD állati modelljeiben, valamint az FXS és ASD diagnózissal rendelkezõ egyéneken |
| CA2974091A1 (en) | 2015-01-15 | 2016-07-21 | Allaysis, Llc | Intravenous baclofen formulations and treatment methods |
| US10172800B2 (en) | 2015-02-20 | 2019-01-08 | Osmotica Kereskedelmi Es Szolgaltato Kft | Controlled release dosage form with enhanced pharmacokinetics |
| US10300032B2 (en) | 2015-02-20 | 2019-05-28 | Osmotica Kereskedelmi Es Szolgaltato Kft | Controlled release dosage form |
| US10987328B2 (en) | 2015-02-20 | 2021-04-27 | Osmotica Kereskedelmi Es Szolgaltato Kft | Controlled release dosage form |
| WO2016132217A1 (en) | 2015-02-20 | 2016-08-25 | Osmotica Kereskedelmi Es Szolgaltato Kft | Method of improving gaba-b receptor agonist therapy |
| IL305342A (en) * | 2015-07-17 | 2023-10-01 | Ovid Therapeutics Inc | Methods for treating developmental disorders with gaboxadol |
| CN109715151A (zh) | 2016-08-11 | 2019-05-03 | 奥维德医疗公司 | 用于治疗癫痫性紊乱的方法和组合物 |
| US10535243B2 (en) * | 2016-10-28 | 2020-01-14 | HBH Development LLC | Target behavior monitoring system |
| US10071083B2 (en) | 2017-02-03 | 2018-09-11 | Ovid Therapeutics Inc | Use of gaboxadol in the treatment of tinnitus |
| JP2020529440A (ja) | 2017-08-04 | 2020-10-08 | オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | 糖尿病および関連する状態の処置におけるガボキサドールの使用 |
| AU2019214891A1 (en) | 2018-01-30 | 2020-08-20 | Apnimed, Inc. (Delaware) | Methods and compositions for treating sleep apnea |
| CA3113644A1 (en) | 2018-09-20 | 2020-03-26 | Ovid Therapeutics Inc. | Use of gaboxadol for the treatment of tourette syndrome, tics and stuttering |
| USD967184S1 (en) * | 2021-02-26 | 2022-10-18 | Oracle International Corporation | Display screen or portion thereof with icon, or paper product with surface ornamentation |
| USD970544S1 (en) * | 2021-02-26 | 2022-11-22 | Oracle International Corporation | Display screen or portion thereof with icon or paper product with surface ornamentation |
| US11523984B1 (en) * | 2021-11-12 | 2022-12-13 | Amneal Pharmaceuticals Llc | Compositions and methods of administering baclofen |
| WO2023178183A1 (en) * | 2022-03-16 | 2023-09-21 | University Of Florida Research Foundation, Incorporated | Combinatorial activation of gaba(b) and alpha-2 adrenergic receptors for treatment of stress induced depression |
Family Cites Families (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3539573A (en) | 1967-03-22 | 1970-11-10 | Jean Schmutz | 11-basic substituted dibenzodiazepines and dibenzothiazepines |
| GB1247067A (en) | 1968-02-16 | 1971-09-22 | Fujisawa Pharmaceutical Co | Tricyclic enol ether compounds and the preparation thereof |
| FR2492258A1 (fr) | 1980-10-17 | 1982-04-23 | Pharmindustrie | Nouveau medicament a base d'amino-2 trifluoromethoxy-6 benzothiazole |
| US4411901A (en) | 1981-12-23 | 1983-10-25 | Mead Johnson & Company | Benzisothiazole and benzisoxazole piperazine derivatives |
| US4804663A (en) | 1985-03-27 | 1989-02-14 | Janssen Pharmaceutica N.V. | 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
| JPH0625181B2 (ja) | 1985-03-27 | 1994-04-06 | 住友製薬株式会社 | 新規なイミド誘導体 |
| IE58370B1 (en) | 1985-04-10 | 1993-09-08 | Lundbeck & Co As H | Indole derivatives |
| GB8607684D0 (en) | 1986-03-27 | 1986-04-30 | Ici America Inc | Thiazepine compounds |
| US4831031A (en) | 1988-01-22 | 1989-05-16 | Pfizer Inc. | Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity |
| DE69010232T2 (de) | 1989-03-03 | 1994-12-01 | Dainippon Pharmaceutical Co | 2-(1-Piperazinyl)-4-phenylcycloalkanpyridin-Derivate, Verfahren zu deren Herstellung und pharmazeutische Zusammensetzungen, die sie enthalten. |
| GB8908085D0 (en) | 1989-04-11 | 1989-05-24 | Lundbeck & Co As H | New therapeutic use |
| US5238945A (en) | 1989-04-11 | 1993-08-24 | H. Lundbeck A/S | Method of treating psychoses |
| EP0402644B1 (en) | 1989-05-19 | 1995-08-16 | Hoechst-Roussel Pharmaceuticals Incorporated | N-(aryloxyalkyl)heteroarylpiperidines and -heteroarylpiperazines,a process for their preparation and their use as medicaments |
| US5229382A (en) | 1990-04-25 | 1993-07-20 | Lilly Industries Limited | 2-methyl-thieno-benzodiazepine |
| US6180337B1 (en) | 1991-05-24 | 2001-01-30 | Baylor College Of Medicine | Diagnosis of the fragile X syndrome |
| US6107025A (en) | 1991-05-24 | 2000-08-22 | Baylor College Of Medicine | Diagnosis of the fragile X syndrome |
| DE4243287A1 (de) | 1992-06-19 | 1993-12-23 | Basf Ag | N-Substituierte Azabicycloheptan-Derivate, ihre Herstellung und Verwendung |
| DE4339702A1 (de) | 1993-11-22 | 1995-05-24 | Bayer Ag | Verfahren zur Herstellung von harten Polyurethanschaumstoffen |
| CZ265096A3 (en) | 1994-03-14 | 1997-06-11 | Novo Nordisk As | Thienoindole derivatives, their use, process of their preparation and pharmaceutical composition containing thereof |
| US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| AU1106195A (en) | 1994-11-09 | 1996-06-06 | Novo Nordisk A/S | Heterocyclic compounds, their preparation and use |
| US6011021A (en) | 1996-06-17 | 2000-01-04 | Guilford Pharmaceuticals Inc. | Methods of cancer treatment using naaladase inhibitors |
| JPH11509846A (ja) | 1995-07-31 | 1999-08-31 | ノボ ノルディスク アクティーゼルスカブ | ヘテロ環式化合物、それらの調製及び使用 |
| AU6514296A (en) | 1995-07-31 | 1997-02-26 | Novo Nordisk A/S | Heterocyclic compounds, their preparation and use |
| GB9609976D0 (en) | 1996-05-13 | 1996-07-17 | Lilly Industries Ltd | Pharmaceutical compounds |
| US5795877A (en) | 1996-12-31 | 1998-08-18 | Guilford Pharmaceuticals Inc. | Inhibitors of NAALADase enzyme activity |
| US5672592A (en) | 1996-06-17 | 1997-09-30 | Guilford Pharmaceuticals Inc. | Certain phosphonomethyl-pentanedioic acid derivatives thereof |
| US6025344A (en) | 1996-06-17 | 2000-02-15 | Guilford Pharmaceuticals Inc. | Certain dioic acid derivatives useful as NAALADase inhibitors |
| US6046180A (en) | 1996-06-17 | 2000-04-04 | Guilford Pharmaceuticals Inc. | NAALADase inhibitors |
| US5863536A (en) | 1996-12-31 | 1999-01-26 | Guilford Pharmaceuticals Inc. | Phosphoramidate derivatives |
| US5902817A (en) | 1997-04-09 | 1999-05-11 | Guilford Pharmaceuticals Inc. | Certain sulfoxide and sulfone derivatives |
| WO1998006724A1 (fr) | 1996-08-09 | 1998-02-19 | Yamanouchi Pharmaceutical Co., Ltd. | Agonistes du recepteur du glutamate metabotropique |
| FR2759366B1 (fr) | 1997-02-11 | 1999-04-16 | Centre Nat Rech Scient | Composes constituant notamment des effecteurs de recepteurs du systeme nerveux central sensibles aux amino acides neuroexcitateurs, leur preparation et leurs applications biologiques |
| CA2285192A1 (en) | 1997-04-07 | 1998-10-15 | Smriti Iyengar | Pharmacological agents |
| WO1998053812A1 (en) | 1997-05-27 | 1998-12-03 | Guilford Pharmaceuticals Inc. | Inhibitors of naaladase enzyme activity |
| TW544448B (en) | 1997-07-11 | 2003-08-01 | Novartis Ag | Pyridine derivatives |
| HUP0004412A3 (en) | 1997-08-14 | 2003-06-30 | Hoffmann La Roche | Use of heterocyclic vinylethers for the preparation of pharmaceutical compositions treating neurological disorders |
| SK2162000A3 (en) * | 1997-08-25 | 2001-03-12 | Neurogen Corp | Substituted 4-oxo-napthyridine-3-carboxamides as gaba brain receptor ligands |
| CN1554649A (zh) | 1997-11-21 | 2004-12-15 | NPSҩ������˾ | 用于治疗中枢神经系统疾病的代谢性谷氨酸受体拮抗剂 |
| EP1059090A4 (en) | 1998-03-03 | 2002-02-27 | Yamanouchi Pharma Co Ltd | DRUGS AGAINST BLEEDING OF THE BRAIN |
| EP1071655A1 (en) | 1998-04-17 | 2001-01-31 | Kenneth Curry | Cubane derivatives as metabotropic glutamate receptor antagonists and process for their preparation |
| SE9802438L (sv) | 1998-07-07 | 1999-07-19 | Laekartjaenster I Vaestsverige | Användning av komposition omfattande minst ett ämne inom gruppen GnRH-analoger för framställning av ett läkemedel för behandling av tvångstanke-tvångshandlingssjukdom |
| US20030216293A1 (en) | 1998-07-07 | 2003-11-20 | Tomas Eriksson | Use of composition comprising at least one substance within the group GnRH-analogues for treatment of obsessive -compulsive disorder (OCD) |
| CA2345137A1 (en) | 1998-10-02 | 2000-04-13 | Novartis Ag | Mglur5 antagonists for the treatment of pain and anxiety |
| GB9823845D0 (en) | 1998-11-02 | 1998-12-23 | Lilly Co Eli | Pharmaceutical compounds |
| GB9823847D0 (en) | 1998-11-02 | 1998-12-23 | Lilly Co Eli | Pharmaceutical compounds |
| TW593241B (en) | 1999-04-20 | 2004-06-21 | Hoffmann La Roche | Carbamic acid derivatives |
| AU4797400A (en) | 1999-05-17 | 2000-12-05 | Eli Lilly And Company | Metabotropic glutamate receptor antagonists |
| ES2249272T3 (es) | 1999-06-02 | 2006-04-01 | Nps Pharmaceuticals, Inc. | Antagonistas de receptores de glutamato metabotropicos y su uso para el tratamiento de enfermedades del sistema nervioso central. |
| US7034055B1 (en) | 1999-06-30 | 2006-04-25 | Prescient Neuropharma Inc. | 2-aminoindane analogs |
| EP1194399A2 (en) | 1999-07-02 | 2002-04-10 | Prescient Neuropharma Inc. | Novel aminoindanes |
| WO2001002367A2 (en) | 1999-07-06 | 2001-01-11 | Eli Lilly And Company | Diester prodrugs of a decahydroisoquinoline-3-carboxylic acid |
| CA2377937A1 (en) | 1999-07-15 | 2001-01-25 | Mcgill University | Oligoneucleotides for metabotropic glutamate receptor type 1 (mglur1) |
| AU6182000A (en) | 1999-08-02 | 2001-02-19 | Yamanouchi Pharmaceutical Co., Ltd. | Remedies for neurogenic pains |
| ES2209728T3 (es) | 1999-08-06 | 2004-07-01 | F. Hoffmann-La Roche Ag | Tetrahidro-benzo(d)azepinas y su uso como antagonistas de receptores de glutamato metabotropico. |
| IL148052A0 (en) * | 1999-08-10 | 2002-09-12 | Uab Research Foundation | Use of gaba antagonists for treatment of spastic disorders, convulsions, and epilepsy |
| US6313159B1 (en) | 1999-08-20 | 2001-11-06 | Guilford Pharmaceuticals Inc. | Metabotropic glutamate receptor ligand derivatives as naaladase inhibitors |
| AU1071301A (en) | 1999-11-01 | 2001-05-14 | Eli Lilly And Company | Pharmaceutical compounds |
| GB0005700D0 (en) | 2000-03-09 | 2000-05-03 | Glaxo Group Ltd | Therapy |
| US20030008897A1 (en) | 2000-03-17 | 2003-01-09 | Mendel Carl M. | Method of controlling weight gain associated with therapeutic drugs |
| US6455553B1 (en) * | 2000-10-03 | 2002-09-24 | Albert Einstein College Of Medicine Of Yeshiva University | Method for treating a demyelinating condition |
| US20020123490A1 (en) | 2001-03-01 | 2002-09-05 | Pfizer Inc. | Combination treatment for anxiety, depression, obsessive compulsive disorder and psychosis |
| US6916821B2 (en) | 2001-04-02 | 2005-07-12 | Brown University | Methods of treating disorders with Group I mGluR antagonists |
| AU2002307049A1 (en) | 2001-04-02 | 2002-10-15 | Brown University Research Foundation | Use of mglur5 antagonists in the manufacture of a medicament in the treatment of autism, mental retardation, schizophrenia |
| US6831077B2 (en) | 2002-07-25 | 2004-12-14 | Comprehensive Neuroscience, Inc. | Augmentation of atypical antipsychotic agent pharmacotherapy with chromium supplementation |
| US6656172B1 (en) * | 2002-09-27 | 2003-12-02 | Medtronic, Inc. | Method for treating severe tinnitus |
| CA2778126A1 (en) | 2003-06-24 | 2005-01-13 | University Of Connecticut | Methods of inhibiting vascular permeability and apoptosis |
| PT1660440E (pt) * | 2003-08-20 | 2012-05-15 | Xenoport Inc | Pró-fármacos de aciloxialquilcarbamato, métodos de síntese e utilização |
| US20050090554A1 (en) * | 2003-09-12 | 2005-04-28 | John Devane | Treatment of gastroparesis and nonulcer dyspepsia with GABAB agonists |
| WO2006012403A1 (en) * | 2004-07-20 | 2006-02-02 | Massachusetts Institute Of Technology | Methods of treatment: cell signaling and glutamate release |
| US20070254314A1 (en) | 2004-09-16 | 2007-11-01 | Geier Mark R | Methods of treating autism and autism spectrum disorders |
| US20060058271A1 (en) | 2004-09-16 | 2006-03-16 | Geier Mark R | Methods for screening, studying, and treating dissorders with a component of mercurial toxicity |
| US9095713B2 (en) * | 2004-12-21 | 2015-08-04 | Allison M. Foster | Methods and systems for treating autism by decreasing neural activity within the brain |
| WO2006121919A2 (en) * | 2005-05-05 | 2006-11-16 | Massachusetts Institute Of Technology | Methods of treating obsessive compulsive disorder |
| WO2007029063A2 (en) * | 2005-07-29 | 2007-03-15 | Ecole Polytechnique Federale De Lausanne (Epfl) | Treatment and/or prevention of pervasive developmental disorders |
| WO2007050741A2 (en) * | 2005-10-26 | 2007-05-03 | Emory University | Compositions for treating fragile x and other disorders methods of use thereof and screening for compounds for fragile x and other disorders |
| AU2006308889A1 (en) * | 2005-10-31 | 2007-05-10 | Braincells, Inc. | GABA receptor mediated modulation of neurogenesis |
| US20070191440A1 (en) * | 2006-01-25 | 2007-08-16 | Solomon Michael E | Methods of treating autism and fragile X syndrome |
| WO2011056849A1 (en) | 2009-11-05 | 2011-05-12 | Massachusetts Institute Of Technology | Methods of treating elevations in mtor signaling |
-
2007
- 2007-11-21 WO PCT/US2007/024311 patent/WO2008066750A1/en active Application Filing
- 2007-11-21 EP EP12184579.6A patent/EP2578216A1/en not_active Withdrawn
- 2007-11-21 SI SI200731879T patent/SI2083811T1/sl unknown
- 2007-11-21 PT PT78621844T patent/PT2083811T/pt unknown
- 2007-11-21 EP EP12184581A patent/EP2567696A1/en not_active Withdrawn
- 2007-11-21 LT LTEP07862184.4T patent/LT2083811T/lt unknown
- 2007-11-21 EP EP07862184.4A patent/EP2083811B1/en active Active
- 2007-11-21 CA CA2670116A patent/CA2670116C/en active Active
- 2007-11-21 HU HUE07862184A patent/HUE032743T2/en unknown
- 2007-11-21 PL PL07862184T patent/PL2083811T3/pl unknown
- 2007-11-21 RS RS20170026A patent/RS55585B1/sr unknown
- 2007-11-21 ES ES07862184.4T patent/ES2610508T3/es active Active
- 2007-11-21 JP JP2009538409A patent/JP2010510314A/ja active Pending
- 2007-11-21 AU AU2007325836A patent/AU2007325836B2/en active Active
- 2007-11-21 DK DK07862184.4T patent/DK2083811T3/en active
-
2009
- 2009-05-14 US US12/454,202 patent/US8143311B2/en active Active
-
2012
- 2012-01-31 US US13/362,985 patent/US8278276B2/en active Active
- 2012-01-31 US US13/362,656 patent/US8273715B2/en active Active
- 2012-09-13 US US13/614,283 patent/US20130012586A1/en not_active Abandoned
- 2012-09-13 US US13/614,715 patent/US20130012587A1/en not_active Abandoned
-
2013
- 2013-06-07 US US13/912,874 patent/US9044443B2/en active Active
-
2017
- 2017-01-05 CY CY20171100014T patent/CY1118406T1/el unknown
- 2017-01-10 HR HRP20170027TT patent/HRP20170027T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PT2083811T (pt) | 2017-01-23 |
| ES2610508T3 (es) | 2017-04-27 |
| SI2083811T1 (sl) | 2017-02-28 |
| HUE032743T2 (en) | 2017-10-30 |
| US8278276B2 (en) | 2012-10-02 |
| EP2567696A1 (en) | 2013-03-13 |
| US20100029770A1 (en) | 2010-02-04 |
| AU2007325836A1 (en) | 2008-06-05 |
| EP2083811A1 (en) | 2009-08-05 |
| US20120122986A1 (en) | 2012-05-17 |
| CA2670116A1 (en) | 2008-06-05 |
| JP2010510314A (ja) | 2010-04-02 |
| US20120129940A1 (en) | 2012-05-24 |
| AU2007325836B2 (en) | 2011-07-21 |
| DK2083811T3 (en) | 2017-01-30 |
| CA2670116C (en) | 2015-03-10 |
| US20130012587A1 (en) | 2013-01-10 |
| LT2083811T (lt) | 2017-01-25 |
| US9044443B2 (en) | 2015-06-02 |
| US8143311B2 (en) | 2012-03-27 |
| EP2083811B1 (en) | 2016-10-26 |
| RS55585B1 (sr) | 2017-06-30 |
| EP2578216A1 (en) | 2013-04-10 |
| CY1118406T1 (el) | 2017-06-28 |
| US8273715B2 (en) | 2012-09-25 |
| US20130261186A1 (en) | 2013-10-03 |
| US20130012586A1 (en) | 2013-01-10 |
| PL2083811T3 (pl) | 2017-05-31 |
| WO2008066750A1 (en) | 2008-06-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20170027T1 (hr) | Postupci liječenja downovog sindroma, sindroma lomljivog kromosoma x i autizma | |
| CO6251212A2 (es) | Tratamiento terapeutico de sindrome metabolico diabetes tipo 2 obesidad o prediabetes | |
| JP2010510314A5 (hr) | ||
| ES2492667T3 (es) | Nuevo uso de ácido(s) graso(s) omega-3 | |
| JP2014517050A5 (hr) | ||
| JP2007238598A5 (hr) | ||
| MA32056B1 (fr) | Suspension pharmaceutique orale contenant du paracetamol et de l'ibuprofene | |
| NZ753024A (en) | The use of inhibitors of bruton’s tyrosine kinase (btk) | |
| BR112013032122A2 (pt) | liberação modificada de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluorometil)fenil] benzamida solubilizada usando ácidos orgânicos | |
| HK1115308A1 (en) | Solid dosage form comprising proton pump inhibitor and suspension made thereof | |
| AR048431A1 (es) | Formulaciones galenicas de compuestos organicos | |
| CO6260019A2 (es) | Metodos para el tratamiento de desordenes gastrointestinales independientes de la ingesta de alimento | |
| ATE539747T1 (de) | Verfahren und medikamente zur verabreichung von ibuprofen | |
| Vijverman et al. | New treatments for the motor symptoms of Parkinson’s disease | |
| NZ587202A (en) | Methods for measuring a patient response upon administration of a drug and compositions thereof | |
| RS54050B1 (en) | FORMULATIONS AND METHODS FOR THE TREATMENT OF AMYLOIDOSIS | |
| BRPI0415953A (pt) | formulação de dosagem de liberação controlada oral, método de tratamento de um distúrbio, conjunto de formas de dosagem de liberação controlada e método para administração da formulação | |
| BR112014009819A2 (pt) | "composições de liberação de fármacos com base em reservatório implantáveis e usos das mesmas" | |
| JP2018138596A5 (hr) | ||
| US20170128446A1 (en) | Use of buspirone metabolites | |
| Eslamian et al. | Effect of 5% benzocaine gel on relieving pain caused by fixed orthodontic appliance activation. A double‐blind randomized controlled trial | |
| MA32722B1 (fr) | Formulation galénique renfermant de l'aliskirène et procédé associé de préparation par granulation par fusion-extrusion | |
| WO2004071152A3 (en) | Use of s-10 hydroxy-10, 11-dihydro-carbamazepine for the treatment of anxiety and bipolar disorders | |
| AR092719A1 (es) | Metodo y composicion para el tratamiento de ectoparasitos | |
| WO2009019307A3 (en) | Oral calcitonin compositions and applications thereof |